biotech · Fabry Disease · Bioequivalence · PLX
Protalix Biotherapeutics
Protalix BioTherapeutics
Protalix Biotherapeutics is a biotech organization headquartered in HACKENSACK, NJ, USA. It trades on NYSE under ticker PLX. Primary therapeutic focus areas include Fabry Disease, Bioequivalence, Gaucher Disease, Upper G
2 Snunit St., Science Park, POB 455, Carmiel, 2161401, IL, HACKENSACK, NJ, USA HQ
1994 Founded
197 Employees
Public company Type
PLX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2 Snunit St., Science Park, POB 455, Carmiel, 2161401, IL, HACKENSACK, NJ, USA
- Founded
- 1994
- Employees
- 197
- Programs
- 21
- Drugs
- 14
- Patents
- 22
PRX-102 (pegunigalsidase alfa)
Phase 3 · mab · Fabry Disease
PRX-102 (pegunigalsidase alfa) for Fabry Disease is a Phase 3 program (mab) at Protalix BioTherapeutics with 3 ClinicalTrials.gov record(s).
Internal code PB-102-F03
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Protalix BioTherapeutics
- Phase
- Phase 3
- Modality
- mab
- Indication
- Fabry Disease
- Status
- completed
- Trials
- 3